1. IGF2BP2 Drives Cell Cycle Progression in Triple‐Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A‐Modified CDK6 Translation Initiation Process.
- Author
-
Xia, Tian, Dai, Xin‐Yuan, Sang, Ming‐Yi, Zhang, Xu, Xu, Feng, Wu, Jing, Shi, Liang, Wei, Ji‐Fu, and Ding, Qiang
- Subjects
- *
TRIPLE-negative breast cancer , *CELL cycle , *CYCLIN-dependent kinase inhibitors , *PHASE transitions , *PROMOTERS (Genetics) , *GENETIC translation , *PROTEIN stability - Abstract
IGF2BP2 is a new identified N6‐methyladenosine (m6A) reader and associated with poor prognosis in many tumors. However, its role and related mechanism in breast cancer, especially in triple‐negative breast cancer (TNBC), remains unclear. In this study, it is found that IGF2BP2 is highly expressed in TNBC due to the lower methylation level in its promoter region. Functional and mechanical studies displayed that IGF2BP2 could promote TNBC proliferation and the G1/S phase transition of the cell cycle via directly regulating CDK6 in an m6A‐dependent manner. Surprising, the regulation of protein levels of CDK6 by IGF2BP2 is related to the changes in translation rate during translation initiation, rather than mRNA stability. Moreover, EIF4A1 is found to be recruited by IGF2BP2 to promote the translation output of CDK6, providing new evidence for a regulatory role of IGF2BP2 between m6A methylation and translation. Downregulation of IGF2BP2 in TNBC cell could enhance the sensitivity to abemaciclib, a CDK4/6 inhibitor. To sum up, our study revealed IGF2BP2 could facilitate the translation output of CDK6 via recruiting EIF4A1 and also provided a potential therapeutic target for the diagnosis and treatment of TNBC, as well as a new strategy for broadening the drug indications for CDK4/6 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF